Literature DB >> 6671185

Amantadine-dyazide interaction.

T W Wilson, A H Rajput.   

Abstract

To document an interaction between amantadine hydrochloride and Dyazide that had apparently produced amantadine toxicity, a patient was given amantadine alone for 1 week, followed by amantadine plus Dyazide for another week, under controlled conditions. A diuretic effect was observed after Dyazide was added to the regimen, but the urine amantadine excretion fell, and the drug's plasma concentration increased. It was concluded that one or both of the components of Dyazide (hydrochlorothiazide and triamterene) reduce the clearance of amantadine and can produce higher plasma concentrations and toxic effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6671185      PMCID: PMC1875821     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  4 in total

1.  Toxic effects of amantadine in patients with renal failure.

Authors:  T S Ing; J T Daugirdas; L S Soung; H L Klawans; S D Mahurkar; J A Hayashi; W P Geis; J E Hano
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

2.  Amantadine-induced heart-failure.

Authors:  J A Vale; K S Maclean
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

3.  The posology of amantadine: a note of caution.

Authors:  T S Ing; J T Daugirdas; L S Soung
Journal:  JAMA       Date:  1980-05-09       Impact factor: 56.272

4.  Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.

Authors:  V W Horadam; J G Sharp; J D Smilack; B H McAnalley; J C Garriott; M K Stephens; R C Prati; D C Brater
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

  4 in total
  10 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

4.  Control of influenza: when do I use amantadine?

Authors:  A McCullough
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

Review 5.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

6.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 7.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 8.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 10.  Parkinson's disease between internal medicine and neurology.

Authors:  Ilona Csoti; Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.